Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 3, 2003, Pages 265-269

  De Candis, Daniela ^a   Stani, Simonetta Chiara ^a   Bidoli, Paolo ^a   Bedini, Vittorio Amedeo ^a   Potepan, Paolo ^a   Navarria, Pierina ^a   Aglione, Stefania ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Induction chemotherapy; Multimodality treatment; Non small cell lung cancer (SCLC); Radiation therapy; Stage III; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; HISTAMINE H3 RECEPTOR ANTAGONIST; MEPREDNISONE; MITOMYCIN; PACLITAXEL; STEROID; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LUNG CANCER; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038517767     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000020583.73928.72     Document Type: Article

References (25)

1. Mountain CF. Revisions in the International System for staging lung cancer. Chest 1997;111:1710-7.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised controlled trials. BMJ 1995;311:899-909.
3. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;47:7-14.
4. Roth J, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomised trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 1998;21:1-6.
5. Langer CJ. Induction or neoadjuvant therapy in resectable non-small cell lung cancer. Semin Oncol 1999;26:34-9.
6. Eberhardt W, Bildat S, Korfee S. Combined modality therapy in NSCLC. Ann Oncol 2000;11:85-95.
7. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
8. Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel (Taxol) in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol 1995;22:2-6.
9. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.
10. Pisters KMW, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000;119:429-39.
11. Bedini AV, Tavecchio L, Gramaglia A, et al. Radiotherapy and concurrent continuous infusion of cisplatin with adjuvant surgery in nonresectable stage III lung carcinoma: short- and long-term results of a phase II study. Int J Radiat Oncol Biol Phys 1999;45: 613-21.
12. WHO handbook for reporting results of cancer treatment. WHO Offset Publication no. 48. Geneva: World Health Organization, 1979.
13. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-73.
15. 1997 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1997;3288
16. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results from Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
17. Eberhardt W, Wilke H, Stametis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-34.
18. Gordon GS, Vokes EE. Chemoradiation for locally advanced unresectable NSCLC. Oncology 1999;13:1075-87.
19. Grunenwald DH, Andre F, Le Pechoux C, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:796-802.
20. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992;10:1237-44.
21. Thomas M, Rübe C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small cell lung cancer. J Clin Oncol 1999;17:1185-93.
22. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998; 16:3316-22.
23. Belani CP, Aisner J, Day R, et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (NSCLC): three year follow up [Abstract 16081]. Proc Am Soc Clin Oncol 1997;16:448a.
24. Choy H, De Vore RD, Hande KR, et al. Preliminary analysis of a phase II study of paclitaxel, carboplatin and hyperfractioned radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol 1997;24:S117-9.
25. Lau D. Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium Phase II Trial. J Clin Oncol 2001;19:442-7.